Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Posts 134-Percent Q3 Revenue Growth as Losses Rise 34 Percent

NEW YORK (GenomeWeb News) — Nanogen yesterday reported that third-quarter revenues bolted upwards 134 percent on dramatic increases in product sales, but the company posted a 34-percent increase in net loss.
Total receipts for the quarter ended Sept. 30 increased to $7.5 million from $3.2 million year over year.
R&D spending in the quarter doubled to $6.2 million, Nanogen said.
Nanogen said net losses for the period swelled to $11.8 million from $8.8 million year over year.
The company said it had around $32.8 million in cash, equivalents, and short-term investments as of Sept. 30.
Nanogen, which last month said it would cut its US headcount by 15 percent by the end of the year in an effort to improve profits, also said it was working to integrate some acquisitions. Among them are Epoch Biosciences, SynX, and Spectral Diagnostics’ cardiac assets.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.